Preparation method and application of endothelium corneum gigeriae galli and angelica sinensis ointment

Abstract

The invention discloses a preparation method and application of an endothelium corneum gigeriae galli and angelica sinensis ointment, and relates to the technical field of traditional Chinese medicine, the endothelium corneum gigeriae galli and angelica sinensis ointment comprises the following raw materials in parts by weight: a medicine solution: 1-3g of angelica sinensis extract and 30-35 parts of endothelium corneum gigeriae An oil phase: 1-5 g of white vaseline, 1-5 g of glycerin monostearate, 10-14 g of stearic acid, 5-8 g of liquid paraffin and 3-6 g of wool fat; a water phase: 0.2 to 0.5 g of triethanolamine, 0.5 to 1 g of glycerin, and 0.1 to 0.5 g of ethylparaben; according to the endothelium corneum gigeriae galli and angelica sinensis ointment, endothelium corneum gigeriae galli and angelica sinensis materials are adopted, endothelium corneum gigeriae galli has the effects of healing sore, promoting tissue regeneration, removing blood stasis and the like, angelica sinensis has the effects of replenishing qi, enriching blood and promoting blood circulation to remove blood stasis, and skin wound healing and capillary regeneration can be effectively promoted, local blood circulation is improved, and inflammatory response is inhibited; meanwhile, the ointment is soft in texture and can absorb percolate and inhibit microbial infection; the method is convenient, economical, practical, good in stability and suitable for application and popularization.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and particularly to the pharmacodynamic research of traditional Chinese medicine chicken gizzard-membrane angelica ointment. Background Art

[0002] Pressure ulcer (PU) is a serious skin and tissue injury caused by long-term mechanical deformation of soft tissues between hard internal structures such as bones or tendons and external support surfaces or medical devices. The results of a systematic review and meta-analysis showed that the global prevalence and incidence of hospital-acquired PU were 12.8%, and the incidence was 5.4 cases per 10,000 patients with PU. The cost of PU treatment varies from country to country, and the treatment cost is relatively high in developed countries; the cost analysis of 273 hospitals in the UK showed that PU costs 750 million pounds per year. The national cost of hospital-acquired PU in the United States is estimated to be 26.8 billion US dollars per year. In addition, the related complications caused by PU can endanger the patient's vital status, and severe cases can be fatal.

[0003] At present, the drugs for the treatment of PU include local antibacterial agents that inhibit wound infection; recombinant bovine basic fibroblast growth factor gel, alginate, hydrogel, etc. that protect the wound and promote the healing of PU; the main goal of chronic wound dressings is to maintain a moist wound environment, prevent or treat infection, and minimize skin irritation or friction between the wound and devices such as clothes or wheelchairs; the traditional Chinese medicine preparations for the treatment of PU include Yunnan Baiyao, moist burn cream, pearl powder, and Sanshi Shengxin ointment, etc.; physical therapies include reconstructive surgery, hyperbaric oxygen therapy, electrical stimulation, and negative pressure wound therapy, and non-surgical therapies such as moxibustion and acupuncture.

[0004] The existing technologies have unique advantages in the treatment of PU. Physical therapy has good curative effects in promoting wound healing, blood circulation, cell repair and regeneration, but at the same time, it has high costs, complex operations, and requires professional personnel support; non-surgical therapies such as moxibustion and acupuncture have individual differences in treatment effects, poor initial curative effects, and need to be adhered to for a long time; the choice of dressings is usually based on wound assessment, the familiarity of doctors and patients with products, availability, and affordability. Recombinant bovine basic fibroblast growth factor gel with recombinant bovine basic fibroblast growth factor as the main component has unique curative effects in the treatment of PU, can promote wound healing, improve local blood circulation, promote capillary regeneration, and reduce inflammatory reactions; but at the same time, it has poor stability, the activity can be affected by contact with protein denaturants, relatively high costs, individual differences, and some patients will have allergic reactions.

[0005] The chicken gizzard-membrane has the effects of promoting sore healing and removing stasis. "Qi Xiao Liang Fang" records that it can stop bleeding and promote sore healing, and treat non-healing sore openings. Angelica sinensis has the effects of replenishing qi and blood, promoting blood circulation to remove stasis. "Treatise on Febrile Diseases" records that it can treat symptoms such as ascending of the root of jueyin disease, oral injury and erosion, and sores, and can promote angiogenesis and wound repair. To solve whether this drug combination can significantly reduce inflammation and the area of pressure sores, reduce the occurrence of related complications, and at the same time promote skin wound healing, promote capillary regeneration, and improve local blood circulation through synergistic effects; it has the advantages of convenient method, economic affordability, good stability, and is suitable for popularization and application. Summary of the Invention

[0006] The purpose of the present invention is to provide a preparation method and application of an ointment of chicken gizzard-membrane and Angelica sinensis. The ointment of chicken gizzard-membrane and Angelica sinensis can be used to treat pressure sores caused by long-term compression or trauma. The present invention verifies the curative effect of the ointment of chicken gizzard-membrane and Angelica sinensis by constructing an animal skin ischemia-reperfusion model, cell cloning, and thiazolyl blue (MTT) method to solve the problems raised in the above background technology.

[0007] To achieve the above purpose, the present invention adopts the following technical solutions: An ointment of chicken gizzard-membrane and Angelica sinensis is composed of the following raw materials in parts by weight:

[0008] Drug solution: 1-3 g of Angelica sinensis extract, 30-35 parts of fine powder of chicken gizzard-membrane;

[0009] Oil phase: 1-5 g of white petrolatum, 1-5 g of glyceryl monostearate, 10-14 g of stearic acid, 5-8 g of liquid paraffin, 3-6 g of lanolin;

[0010] Water phase: 0.2-0.5 g of triethanolamine, 0.5-1 g of glycerol, 0.1-0.5 g of ethylparaben.

[0011] Preferably, the ethylparaben is dissolved by mixing a small amount of pure water and ethanol.

[0012] The present invention provides a preparation method of an ointment of chicken gizzard-membrane and Angelica sinensis, including the following steps:

[0013] (1) Place the Angelica sinensis extract and the fine powder of chicken gizzard-membrane in the same dry beaker, add pure water to dissolve to obtain a drug solution;

[0014] (2) Place the white petrolatum, glyceryl monostearate, stearic acid, liquid paraffin, and lanolin in a dry beaker and heat as the oil phase;

[0015] (3) Place the triethanolamine, glycerol, and ethylparaben in a dry beaker and heat as the water phase;

[0016] (4) When the oil phase and the water phase are heated to 78 °C, first add the drug solution to the water phase, and then slowly add the oil phase to the water phase and stir;

[0017] (5) Then add pure water to make it 100 g, maintain stirring at 78 °C for 10 min, stop heating, and continue stirring until cooled to room temperature to obtain the ointment.

[0018] The present invention also provides the application of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment in the preparation of a drug for treating pressure sores.

[0019] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0020] The Endothelium Corneum Galli Domestici and Angelica sinensis ointment of the present invention uses Endothelium Corneum Galli Domestici and Angelica sinensis as materials. Endothelium Corneum Galli Domestici has the effects of promoting wound healing and stasis removal, and Angelica sinensis has the effects of replenishing qi and blood, promoting blood circulation to remove blood stasis, which can effectively promote the healing of skin wounds, promote the regeneration of capillaries, improve local blood circulation, and inhibit inflammatory reactions; at the same time, the ointment has a soft texture, can absorb exudate, and inhibit microbial infection; it has the advantages of convenient method, economy, good stability, and is suitable for popularization and application. Description of the Drawings

[0021] Figure 1 It is the morphological diagram of the wound area of the rats in the model group of the present invention, where A, B, and C respectively correspond to the morphological diagrams at 3 d, 5 d, and 10 d;

[0022] Figure 2 It is the morphological diagram of the wound area of the rats in the positive group of bFGF of the present invention, where A, B, and C respectively correspond to the morphological diagrams at 3 d, 5 d, and 10 d;

[0023] Figure 3 It is the morphological diagram of the wound area of the rats in the low-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment of the present invention, where A, B, and C respectively correspond to the morphological diagrams at 3 d, 5 d, and 10 d;

[0024] Figure 4 It is the morphological diagram of the wound area of the rats in the medium-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment of the present invention, where A, B, and C respectively correspond to the morphological diagrams at 3 d, 5 d, and 10 d;

[0025] Figure 5 It is the morphological diagram of the wound area of the rats in the high-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment of the present invention, where A, B, and C respectively correspond to the morphological diagrams at 3 d, 5 d, and 10 d;

[0026] Figure 6 It is the histological change (HE) diagram of the wound tissue of the rats at 0 d of drug administration in the present invention;

[0027] Figure 7 It is the histological change (HE) diagram of the wound tissue of the rats at 10 d of drug administration in the present invention, where A, B, C, D, E, and F respectively correspond to the blank group, the model group, the positive group of bFGF, the low-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment, the medium-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment, and the high-dose group of the Endothelium Corneum Galli Domestici and Angelica sinensis ointment;

[0028] Figure 8 Comparison chart of IL-1α levels in the sera and blood of rats in each group of the present invention;

[0029] Figure 9 Comparison chart of TNF-α levels in the sera and blood of rats in each group of the present invention, where n = 6;

[0030] Figure 10 Comparison chart of the proliferative effects of Endothelium Corneum Gigeriae Galli and Angelica sinensis on HaCaT cells in the present invention;

[0031] Figure 11 Comparison chart of the proliferative effects of Endothelium Corneum Gigeriae Galli and Angelica sinensis on HUVEC-C cells in the present invention;

[0032] Figure 12 Comparison chart of the effects of extracts of Endothelium Corneum Gigeriae Galli and Angelica sinensis on cell colony formation in the present invention, where A, B, C, D, E, F, and G respectively correspond to the control group, the low-dose Endothelium Corneum Gigeriae Galli group (10 μg / ml), the medium-dose Endothelium Corneum Gigeriae Galli group (100 μg / ml), the high-dose Endothelium Corneum Gigeriae Galli group (1000 μg / ml), the low-dose Angelica sinensis extract group (10 μg / ml), the medium-dose Angelica sinensis extract group (100 μg / ml), and the high-dose Angelica sinensis extract group (1000 μg / ml). Detailed implementation manners

[0033] In order to further explain the technical solution of the present invention, the following is a detailed elaboration through specific embodiments.

[0034] The present invention provides an Endothelium Corneum Gigeriae Galli and Angelica sinensis ointment, which is composed of the following raw materials in parts by weight:

[0035] Drug solution: 2 g of Angelica sinensis extract and 33 parts of fine powder of Endothelium Corneum Gigeriae Galli;

[0036] Oil phase: 4 g of white petrolatum, 4 g of glyceryl monostearate, 12 g of stearic acid, 7 g of liquid paraffin, 5 g of lanolin

[0037] Aqueous phase: 0.44 g of triethanolamine, 7.5 g of glycerol, 0.3 g of ethylparaben.

[0038] Among them, ethylparaben is dissolved by mixing a small amount of pure water and ethanol. It should be noted that in this embodiment, triethanolamine 0 is an emulsifier, glycerol is a moisturizer, and ethylparaben is a preservative.

[0039] The present invention provides a preparation method of an Endothelium Corneum Gigeriae Galli and Angelica sinensis ointment, including the following steps:

[0040] (1) Place 2 g of Angelica sinensis extract and 33 parts of fine powder of Endothelium Corneum Gigeriae Galli in the same dry beaker, add pure water to dissolve, and obtain a drug solution;

[0041] (2) Place 4 g of white petrolatum, 4 g of glyceryl monostearate, 12 g of stearic acid, 7 g of liquid paraffin, and 5 g of lanolin in a dry beaker and heat as the oil phase;

[0042] (3) Place 0.44 g of triethanolamine, 7.5 g of glycerol, and 0.3 g of ethylparaben in a dry beaker and heat as the water phase;

[0043] (4) When the oil phase and the water phase are heated to 78 °C, first add the drug solution to the water phase, and then slowly add the oil phase to the water phase and stir;

[0044] (5) Then add pure water to 100 g, maintain stirring at 78 °C for 10 min, stop heating, and continue to stir and cool to room temperature to obtain the ointment.

[0045] The present invention also provides the application of the chicken gizzard-membrane angelica ointment in the preparation of a drug for treating pressure sores. The prepared ointment has the effects of replenishing qi and blood, promoting blood circulation to remove blood stasis, and promoting granulation and muscle growth, and can stop bleeding and heal sores and treat unhealed sore openings.

[0046] The present invention constructs a rat skin ischemia-reperfusion I / R model to simulate human pressure injury. By measuring the wound healing rate of rats and detecting serum inflammatory factors, it verifies that the chicken gizzard-membrane angelica ointment can promote skin wound healing, promote capillary regeneration, improve local blood circulation, and inhibit inflammatory reactions; by using the thiazolyl blue (MTT) method to detect the proliferation-promoting effects of chicken gizzard-membrane and angelica on HaCaT and HUVEC-C cells, and the colony formation assay to detect cell colony formation, so as to verify the efficacy of the chicken gizzard-membrane angelica ointment. The specific experiments are as follows:

[0047] 1. Grouping and establishment of the rat bedsore I / R model

[0048] Sixty SPF male SD rats were divided into a blank group, a model group, a low-dose group, a medium-dose group, a high-dose group of compound Jin'ejin Danggui ointment, and a positive control group of bFGF gel according to the random number table method, with 10 rats in each group. After 1 week of acclimatization, the rats were fasted for 12 h, allowed free access to water, and the hair on the right hip of the spine was removed and disinfected. After skin preparation at the same modeling site, the blank control group was not modeled. Parameters such as the size, weight, and magnetic flux of each magnet were measured to ensure no differences. The magnets were placed. The next day, with the midline of the rat's back as the longitudinal axis and the midline of the distance from the rat's front legs to the hind legs as the transverse axis, the distance between the edges and the adsorption positions of the two magnets were marked on the transverse axis 5 mm away from the midline. Except for the blank group, the skin in the skin preparation area on the back of each group of rats was longitudinally lifted by about 5 mm, and two sterilized round magnets were symmetrically adsorbed on both sides of the skin fold, with a 10-mm skin bridge between the two magnets. When a round magnet with a surface magnetic flux of 3000 GS compresses tissue with a thickness of (5.0 ± 2.0) mm, the local pressure is 40 kPa. After local ischemia was caused by compression, the rats were put back into the cage to move freely and eat and drink water. The time of the start of the first cycle of ischemia on the same day and the physiological and behavioral manifestations of the rats were recorded. After the magnets were compressed, the rats needed to be housed individually in a cage to prevent mutual attraction. The external magnets exerted pressure on the iron sheets under the skin, causing local tissue ischemia. After each 12-h ischemia, the external magnets were removed to allow local blood flow to recover for 12 h (reperfusion). This was considered as 1 cycle (IR), and it was carried out continuously for 5 days. Skin darkening, hardening, and non-bleeding ulcers when pricked with a needle were used as the judgment criteria.

[0049] 2. Drug administration

[0050] Drug administration started on the next day. The blank group and the model group were smeared with normal saline; after the other groups were smeared with normal saline, they were administered corresponding drugs. The experimental group evenly applied Jin'ejin Danggui bedsore ointment to the bedsore site with a thickness of about 2 mm, and the positive control group evenly applied bFGF to the bedsore site. The above drug administration was carried out once a day for 10 consecutive days. After drug administration, medical adhesive tape could be used to fix the drug. Note that the original ointment and exudates should be wiped clean before each dressing change. During the experiment, each group of rats was fed with ordinary feed, allowed free access to food and water, and the environment of the rats was kept clean.

[0051] 3. Wound healing morphology

[0052] The wound areas of the rats were measured on days 0, 3, 5, 7, and 10 after drug administration, and the wounds of the rats were scored. The wound morphologies of each group of rats were compared as Figures 1 - 5 shown.

[0053] 4. HE pathological staining

[0054] The skin tissues at the compressed sites of rats were taken, fixed with 4% paraformaldehyde, dehydrated through gradient dehydration, then embedded in paraffin routinely. Serial sections with a thickness of 5 μm were made, dried to form paraffin sections. The sections were dewaxed and hydrated routinely, stained with hematoxylin-eosin (HE) staining solution, dehydrated and cleared with xylene. The processed sections were air-dried and sealed with neutral gum. The pathological changes of the skin tissues of the wound surfaces in each group were observed under a microscope.

[0055] The pathological changes of the skin wound tissues of rats in each group were as Figures 6 - 7 shown. The HE staining results showed that on the 0th day of drug administration, the epidermis, dermis, and subcutaneous tissues were damaged to varying degrees. There were a large number of inflammatory cell infiltrations in the epidermis and dermis layers, the skin appendages disappeared, the wound tissues were severely edematous, the tissues were loose, and there were fibrous degeneration and necrosis. The success of the model establishment was judged by HE staining histopathological detection. On the 10th day of drug administration, the skin structure of the blank group was intact, the epidermis had no necrosis and exfoliation, no bleeding, and no inflammatory cell infiltration; the epidermis layer of the model group had not been repaired completely, there were a large number of inflammatory cell infiltrations in the subcutaneous tissue, a small amount of newly formed capillaries and fibroblasts, accompanied by congestion; the epidermis layer of the bFGF group was basically repaired, there were a small number of inflammatory cell infiltrations in the subcutaneous tissue, a large number of capillaries, fibroblasts could be seen, and a small amount of collagen fibers and granulation tissue were generated; the epidermis layer of the low, medium, and high-dose groups of the chicken gizzard membrane angelica ointment was basically repaired, there were a small number of inflammatory cell infiltrations in the subcutaneous tissue, a large number of capillaries, fibroblasts could be seen, and a small amount of collagen fibers and granulation tissue were generated.

[0056] 5. Detection of the contents of IL-1α and TNF-α by kits

[0057] After the rats in each group were anesthetized, 5 mL of abdominal aortic blood was taken respectively, centrifuged at 3000 r·min-1 at 4 °C for 15 min, the serum was separated and aliquoted into centrifuge tubes, and stored in a -80 °C refrigerator for later use. Strictly in accordance with the kit instructions, the contents of IL-1α and TNF-α were detected by an enzyme-linked immunosorbent assay (ELISA) kit.

[0058] The comparison of the levels of IL-1α and TNF-α in the blood of rats in each group was as Figures 8 - 9 shown. After 10 days of treatment, compared with the blank group, the levels of serum IL-1α and TNF-α in the model group were significantly higher than those in the blank group (P < 0.05); compared with the model group, the levels of serum IL-1α and TNF-α in the bFGF positive group and the medium and high-dose groups of the chicken gizzard membrane angelica ointment were significantly lower than those in the model group (P < 0.05). The level of serum IL-1α in the low-dose group of the chicken gizzard membrane angelica ointment was significantly lower than that in the model group (P < 0.05). There was no significant difference in the levels of serum TNF-α between the low-dose group of the chicken gizzard membrane angelica ointment and the model group (P > 0.05).

[0059] 6. Detection of the proliferation of HaCaT and HUVEC-C cells by the thiazolyl blue (MTT) method

[0060] After digestion with 0.25% trypsin, the cell concentrations of HaCaT cells and HUVEC-C cells were adjusted to approximately 5×10^4 / well, seeded in 96-well plates with 3 replicates, and continued to be cultured until the cell confluence was greater than 50%; Weighed the extracts of chicken gizzard-membrane and angelica sinensis, dissolved them in a small amount of DMSO until completely dissolved, and the concentration of the prepared stock solution was 500 mg / ml; According to the maximum limit that DMSO has no obvious growth effect on cells, the maximum concentration of the pre-experiment concentration gradient was set to 1 mg / ml; The zero-adjustment well was 100 μL of complete medium, the Control group was normal cells added with 100 μL of complete medium, and the drug-added groups were replaced with complete medium containing different drug concentrations, and continued to be cultured for 48 h; 90 μL of fresh medium was replaced in each well, 10 μL of MTT was added to each well, and incubated in the dark at 37 °C in a 5% CO2 incubator for 4 h. The liquid in the wells was aspirated clean, 100 μL of DMSO was added, and shaken at room temperature on a shaker for 10 min. The OD value at the same time point was measured by an enzyme-labeling instrument at a wavelength of 570 nm.

[0061] Comparison of the proliferation effects of thiazolyl blue (MTT) on HaCaT and HUVEC-C cells, as Figures 10 - 11 shown, chicken gizzard-membrane promoted the proliferation of HaCaT and HUVEC-C cells, and showed concentration-gradient dependence and a positive correlation, and had a significant effect on HUVEC-C. The extract of angelica sinensis had no obvious growth-promoting effect on HaCaT; but significantly promoted the proliferation of HUVEC-C cells, and showed concentration-gradient dependence and a positive correlation.

[0062] 7. Clone formation experiment to detect cell colony formation

[0063] Take the HUVEC-C cell line in the logarithmic growth phase, inoculate 800 cells / well in 12-well plates with 3 replicates in each group: the control group medium was normal high-glucose medium, and the other groups were medium containing corresponding concentrations of chicken gizzard-membrane and angelica sinensis extracts; continued to be cultured for 10 days, fixed with methanol for 30 min, stained with Giemsa, and photographed at an objective lens magnification of 4X.

[0064] Comparison of the effects of chicken gizzard-membrane and angelica sinensis extracts on cell colony formation, as Figure 12 shown, compared with the control group, chicken gizzard-membrane and angelica sinensis extracts promoted cell colony formation and showed concentration dependence.

[0065] 8. Data analysis

[0066] SPSS 25.0 was used for statistical analysis of the data. When measurement data satisfied normality and homogeneity of variance, they were expressed as mean ± standard deviation. The t-test was used for comparison between two groups, and one-way analysis of variance (ANOVA) was used for comparison among multiple groups. Repeated-measures ANOVA was used for data with repeated measurements. Otherwise, the experimental data were expressed as the interquartile range and median. All statistical tests were two-sided tests, with a significance level of α = 0.05. A P < 0.05 was considered statistically significant, and a P < 0.01 was considered extremely statistically significant.

[0067] In summary, the Jin'ejin Danggui ointment of the present invention uses Jin'ejin and Danggui materials. Jin'ejin has the effects of promoting granulation and muscle growth and being good at removing stasis, and Danggui has the effects of tonifying qi and nourishing blood and promoting blood circulation to remove stasis. It can effectively promote the healing of skin wounds, promote the regeneration of capillaries, improve local blood circulation, and inhibit inflammatory reactions. At the same time, the ointment has a soft texture, can absorb exudate, and inhibit microbial infections. It has the advantages of convenient method, economy, good stability, and is suitable for popularization and application.

[0068] The above are only the preferred examples of the present invention and are not used to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or perform equivalent replacements for some of the technical features. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. A chicken gizzard-skin angelica ointment, characterized in that It is composed of the following raw materials in parts by weight: Drug solution: 1 - 3 g of angelica extract and 30 - 35 parts of fine powder of chicken gizzard-membrane; Oil phase: 1 - 5 g of white petrolatum, 1 - 5 g of glycerol monostearate, 10 - 14 g of stearic acid, 5 - 8 g of liquid paraffin, 3 - 6 g of lanolin; Water phase: 0.2 - 0.5 g of triethanolamine, 0.5 - 1 g of glycerol, 0.1 - 0.5 g of ethylparaben.

2. The chicken gizzard membrane angelica ointment according to claim 1, wherein: The ethylparaben is dissolved by mixing a small amount of pure water and ethanol.

3. The preparation method of a kind of chicken gizzard-membrane angelica ointment according to any one of claims 1-2, characterized in that: It includes the following steps: (1) Place the angelica extract and the fine powder of chicken gizzard-membrane in the same dry beaker, add pure water to dissolve, and obtain the drug solution; (2) Place the white petrolatum, glycerol monostearate, stearic acid, liquid paraffin, and lanolin in a dry beaker, and heat as the oil phase; (3) Place the triethanolamine, glycerol, and ethylparaben in a dry beaker, and heat as the water phase; (4) When the oil phase and the water phase are heated to 78 °C, first add the drug solution to the water phase, and then slowly add the oil phase to the water phase, and stir; (5) Then add pure water to 100 g, maintain stirring at 78 °C for 10 min, stop heating, and continue to stir and cool to room temperature to obtain the ointment.

4. Use of the chicken gizzard-membrane and angelica ointment according to any one of claims 1 - 2 in the preparation of a drug for treating pressure ulcers.

Images